Protagonist Therapeutics shareholders approve doubling of authorized common shares to 180M

Protagonist Therapeutics, Inc

Shareholders approved amendment to increase authorized common shares from 90M to 180M, effective June 21, 2024.
Three Class II directors elected: Sarah O'Dowd, William Waddill, and Rusty Williams.
Advisory vote on executive compensation approved: 33.9M for, 9.3M against.
Ratification of Ernst & Young as independent auditor for FY2024 approved: 49.3M for, 115k against.
All four proposals passed; no other matters submitted at annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.